Mavacamten Promising in Non-Obstructive HCM

]]>(MedPage Today) -- The investigative agent mavacamten may be safe and effective in patients with non-obstructive hypertrophic cardiomyopathy (HCM), researchers reported.In the primary safety endpoint of the MAVERICK HCM trial, 10.3% of patients...